Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine modelsHarold B. Brooks(Eli Lilly (United States)), F. George Njoroge(Eli Lilly (United States))Scientific ReportsOctober 12, 201810.1038/s41598-018-33453-4Cited by 21SaveCiteExport RISWatch citationsRelated PapersCharacterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity|Molecular Cancer Therapeutics|2013|121Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity|Unknown|2023|0Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity|Unknown|2023|0Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity|Unknown|2023|0Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity|Unknown|2023|0